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ABSTRACT
Temporal processing by cochlear implant listeners is
degraded and is affected by auditory deprivation. The
fast-acting Kv3.1 potassium channel is important for
sustained temporally accurate firing and is also
susceptible to deprivation, the effects of which can
be partially restored in animals by the molecule
AUT00063. We report the results of a randomised
placebo-controlled double-blind study on psychophys-
ical tests of the effects of AUT00063 on temporal
processing by CI listeners. The study measured the
upper limit of temporal pitch, gap detection, and
discrimination of low rates (centred on 120 pps) for
monopolar pulse trains presented to an apical elec-
trode. The upper limit was measured using the
optimally efficient midpoint comparison (MPC)
pitch-ranking procedure; thresholds were obtained
for the other two measures using an adaptive proce-
dure. Twelve CI users (MedEl and Cochlear) were
tested before and after two periods of AUT00063 or
placebo in a within-subject crossover study. No
significant differences occurred between post-drug
and post-placebo conditions. This absence of effect
occurred despite high test-retest reliability for all
three measures, obtained by comparing performance
on the two baseline visits, and despite the demon-
strated sensitivity of the measures to modest changes
in temporal processing obtained in other studies from
our laboratory. Hence, we have no evidence that
AUT00063 improves temporal processing for the
doses and patient population employed.
Keywords: temporal processing, AUT00063, kv3.1,
cochlear implant (CI), rate discrimination ratio
(RDR), gap detection threshold (GDT), midpoint
comparison procedure (MPC)
INTRODUCTION
Despite the success of cochlear implants (CIs) in
restoring hearing to more than half a million people
worldwide, auditory perception by CI listeners suffers
from fundamental limitations in spatial selectivity and
in temporal processing compared to normal hearing
(NH). Both of these can be revealed using psycho-
physical and physiological experiments in which
simple stimuli are presented to one or more CI
electrodes.
Limitations in spatial selectivity are reflected in the
broad spread of neural excitation resulting from
stimulation of a single electrode, as measured both
using psychophysical techniques in humans and
neural recordings in animals (Shannon 1983;
Middlebrooks and Bierer 2002; Snyder et al. 2004;
Carlyon et al. 2017). The processing of temporal fine
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structure (TFS) is also limited. When a single elec-
trode is stimulated at moderate rates, pitch increases
with increasing rate but the minimum detectable rate
difference is usually substantially larger than for pure
tones in NH (Moore and Carlyon 2005). As rate
increases further, pitch no longer increases once the
rate exceeds an upper limit, which varies between
about 200–700 pps depending on the listener and on
the electrode stimulated (Townshend et al. 1987;
Kong and Carlyon 2009; Carlyon et al. submitted).
When bandpass filtered harmonic complexes, de-
signed to minimise place of excitation cues to pitch,
are presented to normal hearing listeners the highest
upper limit observed is approximately 700 pps
(Macherey and Carlyon 2014). This is consistent with
the upper limit in the Bbest^ CI listeners being
approximately equal to that obtained in NH, but with
many CI subjects showing a much lower limit.
A possible neural correlate of the upper limit has
been observed in single-neuron recordings in the
inferior colliculus (IC) of anaesthetized cats, which
phase lock to electrical pulse trains up to a certain
rate beyond which they exhibit only an onset response
(Snyder et al. 1995; Vollmer et al. 2005; Middlebrooks
2008; Middlebrooks and Snyder 2010; Hancock et al.
2013; Vollmer et al. 2017). Although it is not known
whether the limitation arises at or before the IC, there
is evidence from humans that the limitations on TFS
processing arise centrally to the auditory nerve (AN).
We have measured the electrically evoked compound
action potential (ECAP) and pulse-rate discrimination
in the same subjects, and found good encoding of
pulse rate in the ECAPs even at rates where behav-
ioural discrimination was at chance (Carlyon and
Deeks 2015).
There is direct evidence that the physiological
upper limit of temporal processing is reduced by
auditory deprivation. For example, juvenile deafened
cats show a higher limit when they have grown up
listening through a CI than when they have grown up
deaf (Hancock et al. 2013; Vollmer et al. 2017).
Indirect evidence from humans, consistent with an
effect of auditory deprivation and chronic stimulation
on the psychophysical upper limit, comes from the
finding in one study that it correlates negatively with
the duration of deafness (Cosentino et al. 2016).
There is also some evidence, discussed in BEfficacy^
under the BDiscussion^ section, that in both cats and
humans, the upper limit following auditory depriva-
tion can be increased by a period of chronic
stimulation (Vollmer et al. 2005; Carlyon et al.
submitted).
Fine temporal processing in the auditory system
relies on the ability of neurons, at and central to the
AN, to fire in a sustained and temporally accurate
fashion at high stimulus repetition rates (Song et al.
2005). This firing property is dependent on the
expression of Kv3 high-voltage-activated potassium
channels. Kv3 channels are activated by depolariza-
tion of the plasma membrane to potentials above −
20 mV; they open rapidly during the depolarising
phase of the action potential in order to initiate
repolarisation and prevent significant sodium channel
inactivation. As the neuron begins to repolarise, the
channels deactivate quickly and thus do not contrib-
ute significantly to the after-hyperpolarisation (Rudy
et al. 1999; Rudy and McBain 2001). As a conse-
quence, neurons expressing Kv3 channels are able to
sustain action potential firing at high frequencies.
Kv3.1 and Kv3.3 channel subtypes are expressed in
fast spiking neurons throughout the auditory
brainstem (Grigg et al. 2000; Li et al. 2001). Loss of
Kv3.1 channel expression in the auditory brainstem is
associated with ageing (Jung et al. 2005; Zettel et al.
2007) and with auditory deprivation arising from
hearing impairment (von Hehn et al. 2004).
AUT00063 is a novel small-molecule drug that
selectively enhances Kv3 channel function. In vitro
electrophysiology studies with recombinant human
Kv3.1 channels expressed in mammalian cells have
shown that AUT00063 can increase the amplitude of
hKv3.1-mediated potassium currents with a pEC50’s of
5.1 ± 0.17 (Anderson et al. 2018). In addition, two
studies showed that AUT00063 reduces the elevation
in spontaneous firing rate that results from noise
exposure, both in the dorsal cochlear nucleus
(BDCN^: Glait et al. 2018) and IC (Anderson et al.
2018). Those studies also showed that AUT00063 can
increase neural thresholds (Glait et al. 2018) and
reduce driven rates (Anderson et al. 2018) to acoustic
stimulation. More importantly for the present study, it
has been shown that AUT00063 can improve fine
temporal coding in the auditory brainstem in mice.
Chambers et al. (2017) exploited their previous
finding (Chambers et al. 2016) that Oubain adminis-
tration, which killed 95 % of AN type 1 neurons,
degraded the temporal representation of trains of
acoustic chirps in the IC and auditory cortex, and
showed that this degradation could be partially
reversed by AUT00063, in vivo. Specifically, they
demonstrated that AUT00063 increased the precision
of phase locking in the IC, particularly at pulse rates
faster than about 40 Hz, and improved the accuracy of
a classifier that was trained to decode pulse rate from
the responses of cells in the IC or auditory cortex.
They also showed that, in vitro, AUT00063 reduced
the width and increased the precision of action
potentials recorded from fusiform neurons of the
DCN, which provide a principal input to the IC.
Further evidence for the effect of AUT00063 on
temporal coding comes from a preliminary report
showing that, whereas aged rats exhibit higher gap
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detection thresholds than younger rats, this elevation
can be partially reversed by AUT00063 (Rybalko et al.
2014).
Two previous clinical trials of the effect of
AUT00063 on acoustic hearing confirmed the safety
of the drug at doses up to 800 mg/day, but revealed
no significant effect on either tinnitus or on speech
perception in people with hearing loss in older age
(Autifony Therapeutics 2014, 2017b). However, acous-
tic studies of the effects of auditory deprivation, and
its possible amelioration by a pharmaceutical agent,
are limited by the fact that one can only test patients
who have some useable residual hearing. This neces-
sarily excludes those patients who will have experi-
enced most deprivation, namely those who are
profoundly deaf. CIs provide an almost unique
opportunity to study such patients. Accordingly,
Autifony Therapeutics Ltd., who are the inventors of
AUT00063, decided to test its effects on hearing
among profoundly deaf patients whose hearing was
restored by a CI. The initial design of this
BQuicK+fire^ trial tested speech and music perception
using stimuli presented via the patients’ clinical
processor, and the results of those investigations are
described elsewhere (Sanchez et al. 2018). However,
as the clinical processors typically remove TFS, and
because AUT00063 has been shown to restore the
processing of fine temporal information, we decided
to evaluate it using direct-stimulation psychophysical
experiments that were designed to measure temporal
processing by CI users. To do so, we used tests that
were well-established in our laboratory and that we
had shown to be sufficiently sensitive to modest effects
of chronic stimulation and/or stimulus level (Carlyon
et al. submitted). The rationale was to maximise the
possibility of observing a significant effect by using
methods that measure the processing that the drug
was designed to improve. If—as turned out to be the
case—no significant benefits were found, one could
exclude the explanations that either the CI processor
removed the appropriate (TFS) information, and/or
that the tests were not sufficiently sensitive to reveal a
significant effect.
METHODS
Overview of Protocol and Subject Selection
A randomised placebo-controlled crossover design
was used. Subjects were tested on four occasions,
before and after two 28-day periods of taking
AUT00063 or a placebo daily, with a 3-week washout
period between the second and third testing sessions
(Fig. 1). To accommodate the logistics of testing
patients from geographically distributed sites, the
testing schedule was amended for the tests described
here, such that post-dose tests (sessions 2 and 4) could
take place at any point between the 20th day after
dosing began and the day after the last dose; the
actual testing points for the AUT00063 condition are
shown for each subject in Table 1. There was no
significant difference between AUT00063 and placebo
conditions for the average number of days after the
initial dose that testing was performed. The
AUT00063 dosage consisted of four 200 mg capsules
once daily; placebo capsules were visually identical to
the drug capsules. Subjects were randomly assigned to
two groups, which differed only in the order in which
AUT00063 and the placebo were administered.
Twelve subjects were initially recruited from four
clinical sites in the UK, based in London, Cambridge,
Manchester, and Birmingham. They received travel
expenses and an honorarium for taking part. Inclu-
sion criteria included unilateral implantation with
MedEl, Cochlear, or Advanced Bionics devices within
the previous 9 to 48 months, BKB audio-only speech
scores of between 25 and 95 %, English as first
language, and at least 80 % of the electrode array
functioning and mapped. A non-exhaustive list of
exclusion criteria consisted of subjects with severe
tinnitus, those suffering from anxiety or depression,
those taking CNS-penetrant medication prohibited by
the study protocol, pregnant or nursing women, and
people with major diseases that were likely to be
jeopardised by entering the study. Further details of
the inclusion and exclusion criteria are available at
the US public registry and at the European Clinical
Trials Register, where the study was registered
(Autifony Therapeutics 2017a, c). Three subjects
dropped out of the study before completion and were
replaced; only the results of the 12 subjects who
completed the study are reported here. Because of
the blinding it was not possible to ensure that the new
subjects had been assigned to the same groups as
those they had replaced. Of the final sample, eight
were administered AUT00063 followed by placebo,
and four with placebo followed by AUT00063. Five
were implanted with a MedEl device and seven with a
Cochlear device; further information on subjects and
device type is given in Table 1.
All methods were described in a testing manual
that was prepared by the first author’s laboratory and
1 2 3 4Session:
Fig. 1. Schematic illustration of the experimental design
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approved by the sponsor prior to the start of the
study. Similarly, all statistical analyses of AUT00063’s
safety and efficacy were described in a Statistical
Analysis Plan prepared by the Contract Research
Organisation, SynteractHCR, according to ICH E9
guidelines and was finalised prior to unblinding of
treatment assignments. Additional analyses, for exam-
ple those concerning test-retest reliability and corre-
lations between the different tests, were performed
and specified subsequently by the authors. Following
completion of the testing and prior to unblinding of
treatment assignments, a blind data review meeting
considered any protocol deviations. No substantial
deviations, which would have resulted in subjects
being excluded from the analysis, were identified.
Psychophysical Testing
Overview. Each testing session lasted approximately 2–
3 h and consisted of psychophysical tests performed
on an apical electrode of the patient’s device. This was
electrode 4 for MedEL users and electrode 20 for
Cochlear users. The measures of interest were rate
discrimination of pulse trains with rates centred on
120 pps, the upper limit of temporal pitch obtained
using a pitch-ranking procedure with pulse rates
between 90 and 981 pps, and gap detection thresholds
for 1055-pps pulse trains. They are described in detail
below.
The same general method was used for all subjects,
regardless of the device they were implanted with. In
particular, we always used a dB scale to adjust current
levels, even though current level is usually specified in
linear units for the MedEL device. All stimuli
consisted of trains of symmetric cathodic-first biphasic
pulses. All pulses had a duration of 43 μs/phase and
an inter-phase gap of 0 μs (MedEl) or 8 μs (Cochlear);
the difference between these two values is very small
relative to the integration time constant of the nerve
membrane (e.g. Boulet et al. 2016) and is unlikely to
have influenced the results. All stimulation was in
monopolar mode; for the Cochlear device both extra-
cochlear electrodes were connected in parallel
(MP1+2 mode). The same program, written in Matlab,
was used to control stimulus presentation and record
responses for both devices. The program called low-
level routines provided by the respective implant
manufacturers as part of the NIC3 (Cochlear) and
RIB2 (MedEl) software packages. All stimuli were
checked using a test implant and digital storage
oscilloscope. In accordance with standard practice in
our laboratory, impedances were checked at the start
and end of every testing session.
Loudness Judgements. It was considered important to
equate stimuli in the temporal processing tasks for
approximately equal loudness, so as to discourage the
use of any potential loudness cues. Each session
therefore began with the measurement of most
comfortable levels (MCLs) for pulse trains having
rates of 90, 162, 399, and 981 pps, in that order.
Subjects indicated the loudness of the pulse trains
using a chart on which loudness was marked on a
scale from 0 (‘off’) to 10 (Btoo loud^). The experi-
menter gradually increased the stimulus level until
level 7 (Bloud but comfortable^) was reached, and
then reduced it until the subject indicated a loudness
corresponding to point 6 (MCL). After the MCL had
been obtained for all rates it was then re-measured for
the 90-pps stimulus. The result from this second
measurement typically fell within 0.5 dB of that
obtained for the first measurement, and was used for
the next stage. This consisted of a series of loudness
TABLE 1
Details of the patients who completed the study. BOrder^ refers to the order of testing, where 1-AUT00063 followed by placebo
and 2 = placebo followed by AUT00063. BAUT test day^ shows the number days after the first dose on which the tests were
performed in the AUT00063 condition. The last two columns show the RMS errors between the broken-stick fit and the data in
the upper-limit measures for AUT00063 and placebo, respectively
Subject Age (years) Deafness duration (years) Device Order AUT test day RMSE (AUT) RMSE (placebo)
S01 76 1.5 Cochlear 1 21 0.43 0.38
S02 58 51.6 Cochlear 1 22 0.31 0.39
S03 78 36.8 Cochlear 1 21 0.31 0.47
S04 73 26.2a Cochlear 1 28 1.10 0.99
S05 69 0.6 Cochlear 1 21 0.76 0.83
S06 63 4.0 Cochlear 2 23 1.27 0.86
S07 63 4.2 Cochlear 2 23 0.66 1.19
S08 79 6.5 Med El 1 23 0.57 0.54
S09 46 30.1 Med El 2 21 0.66 0.84
S10 73 11.2 Med El 1 22 0.22 0.36
S11 68 2.0 Med El 1 22 0.81 0.38
S12 82 1.8 Med El 2 21 0.67 0.73
aDuration given for this subject is time since first aided; the time since onset of hearing loss was 43.8 years
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balances, starting with the 90-pps stimulus presented
at its MCL, and with the subject adjusting the level of
the 162-pps stimulus to be equal in level. This adjusted
level was then presented as the fixed stimulus, and the
subject adjusted the level of the 90-pps stimulus so as
to match its loudness. This was done so as to control
for any biases towards under- or over-adjusting the
variable stimulus. The difference between the final
levels of the two stimuli was averaged for these two
stages, and used to determine the final level of the
162-pps stimulus. This procedure was then repeated,
matching 399 pps to 162 pps (with the 162 pps pulse
train initially fixed at the previously obtained matched
level) and then 981 pps to 399 pps. The levels used for
all subsequent stimuli in the low-rate discrimination
and upper-limit measurements (see below) were
obtained by straight-line interpolation of adjacent
rates and levels on a log rate vs dB scale.
Low-Rate Discrimination. Following loudness estimation
we measured rate discrimination thresholds for pairs
of pulse trains with rates geometrically centred on 120
pps, using an adaptive procedure (Levitt 1971). In
each two-interval forced-choice trial the subject was
required to indicate the interval containing the
higher pitch, and the response was scored as correct
whenever this corresponded to the higher-rate pulse
train. Initially subjects performed ten practice trials
with pulse rates of 90 and 160 pps. The adaptive
procedure started with these pulse rates, and the rate
difference was reduced by a factor of 1.25 after every
three consecutive correct responses and increased by
the same factor after every incorrect response. Stim-
ulus levels were interpolated from the MCL loudness
function for each subject. In two cases, both in the
first session, the difference between 90 and 160 pps
was not discriminable and so caused the lower rate to
drop below 90 pps. In those instances the level was set
to be the same as that for the 90-pps pulse train. This
was done because MCLs vary only slightly with rate
decreases below about 100 pps (McKay and
McDermott 1998). Correct-answer feedback was pro-
vided after every trial. Each change from decreasing
to increasing rate difference or vice versa was defined
as a turnpoint. The step size was reduced to a factor of
1.1 after the first two turnpoints. The adaptive run
ended after eight turnpoints and the threshold,
defined as the ratio of the higher and lower pulse
rates, was calculated from the geometric mean of the
last six turnpoints. The adaptive procedure was then
repeated twice. If the standard deviation of the
turnpoints for any run exceeded 1.37 an extra run
was performed. This criterion was selected as equal to
the 95th centile observed in pilot experiments with a
different group of subjects. The geometric mean of all
three or four rate discrimination ratios (RDRs) was
calculated and entered into the analyses.
Upper Limit of Temporal Pitch. Following the adaptive
procedure listeners pitch-ranked eight pulse rates,
equally spaced on a log scale between 120 and 981 pps,
using the optimally efficient midpoint comparison
procedure (Long et al. 2005). This procedure consists
of a series of 2IFC trials without feedback. The
procedure was run 10 times, each with the stimuli
introduced in a different random order, and the pitch
rank for each stimulus was calculated from the mean of
these 10 Bsub-blocks^. The pitch-rank function was then
fit with a Bbroken stick^, using the Curve Fitting Toolbox
fromMatlab. The upper limit of pitch was defined as the
rate corresponding to the intersection of two straight
lines. Examples of four broken-stick fits are shown in
Fig. 2. To fit the broken-stick function, the x-axis values
were first transformed to be between 1 and 8, the
number of rates. The constraints were respectively [1, 3]
and [− 0.1, 0] for the slopes of the first and second
straight lines, [− 10, 1] for the constant term of the first
line, and [1, 8] for the x value of the intersection
between the two lines. Corresponding start values for
the fitting procedure were 1, 0, 0 and 4.5. These fitting
parameters were selected in advance by inspecting
approximately 120 functions obtained in our laboratory
from previous experiments, and choosing a set of
parameters that yielded upper limits that corresponded
well to visual estimates and that were not unduly affected
by occasional outliers.
Gap Detection. Finally we measured gap detection
thresholds (GDTs) for 1033-pps pulse trains, present-
ed at the same level as for the upper-limit measures at
a pulse rate of 981 pps. The nominal duration of
each pulse train was 400 ms but this was roved by ±
10 % for each stimulus presentation, so as to avoid
the use of any duration cues caused by introducing
the gap in the signal interval. In each two-interval
forced-choice trial listeners discriminated between an
uninterrupted pulse train and one with a gap mid-way
through. Correct-answer feedback was provided after
every trial. At the start of the procedure the gap
duration was 40 ms. This was reduced by 40 % after
every three consecutive correct answers, and in-
creased by the same percentage after every incorrect
answer. The change from decreasing to increasing
gap size, or vice versa, defined a turnpoint, and the
step size was reduced to 10 % after the first two
turnpoints. Each run ended after eight turnpoints,
and the geometric mean of the last six was averaged
to obtain the GDT for each run. The procedure was
then repeated twice. If the standard deviation of the
turnpoints for any run exceeded 1.33 ms an extra run
was performed. This criterion was selected as equal to
the 95th centile observed in pilot experiments with a
different group of subjects. The geometric mean of
all three or four GDTs was calculated and entered
into the analyses.
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RESULTS
Correlations Between Sessions and Tasks
Figure 3 shows the across-subject correlations between
the two baseline visits (sessions 1 and 3 in Fig. 1) for
the low-rate RDR, upper limit, and GDTs respectively.
As with all analyses reported here, the calculations
were performed on the (natural) log-transformed
scores and plotted using the untransformed scores
on a logarithmic scale. Test-retest reliability was high
for all three tests, with Pearson correlation co-
efficients of 0.94, 0.83, and 0.96 respectively (t(10) =
8.71, 4.71, and 10.84, p G 0.0001 in all cases). A series
of t tests revealed no evidence for any change in
performance between sessions 1 and 3 for the upper
limit (t(11) = 0.68, p = 0.51). However, thresholds in
the other two tests decreased significantly between
sessions 1 and 3. The RDR decreased from 1.26 to
1.15 (t(11) = 3.38, p = 0.006) and the GDT decreased
from 3.40 to 2.91 ms (t(11) = 3.28, p = 0.007). Note that
these improvements in the average RDRs and GDTs
between sessions 1 and 3 represent learning effects
that are not reflected in the test-retest correlations
described above. The fact that the RDRs and GDTs
improved from sessions 1 to 3 whereas the upper limit
did not may be related to the fact that correct answer
feedback was provided only for the RDR and GDT
tests.
Although each test showed good test-retest reliabil-
ity with highly significant correlations between ses-
sions 1 and 3, correlations between tests were modest
and non-significant. When measures were averaged
(a) (b)
(c) (d)
FIG. 2. Examples of pitch-ranking functions and the associated broken-stick fits. The subject identifier, condition, and rms error between the
broken-stick fit and the pitch ranks are shown at the top of each panel
Upper limit, ppsRate discrimination, ratio Gap detection, ms(a) (b) (c)
FIG. 3. Scatterplots showing performance on visits 1 vs 3 for the a low-rate discrimination, b pitch ranking, and c gap detection tasks
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across sessions 1 and 3, the correlation between the
RDR and the upper limit was − 0.20 (t(10) = 0.65, p =
0.53), that between the GDT and the upper limit was
− 0.27 (t(10) = 0.89, p = 0.40), and that between the
GDT and the RDR was − 0.07 (t(10) = 0.41, p = 0.83).
Efficacy
For each test, the results from the two post-treatment
measures (sessions 2 and 4) were entered into an analysis
of variancemodel with treatment, sequence, subject within
sequence, and period as fixed factors (Grizzle 1965). The
analysis was performedusing the SAS statistical package. In
each case the crucial outcomes are the mean and 95 %
confidence limits for the effect size, defined as the ratio
between the scores in the AUT00063 and placebo
conditions. These are shown in bold in Table 2 along with
themeans for each condition and significance levels for all
main effects. Note that good performance corresponds to
higher values of the upper limit but to lower values of the
RDR and GDT. There was no significant effect of
treatment for any measure, and the confidence limits for
the treatment effect size all encompass unity.
The results of the AUT00063 and of placebo condi-
tions are shown for each test in Fig. 4; coloured lines and
symbols show data for individual subjects, withmean data
indicated by the thick black lines and filled squares. Error
bars show standard errors. Figure 5 shows the same data
expressed as the ratio of the AUT00063/placebo scores
for the rate discrimination, upper limit, and gap
detection tests. Both figures illustrate the absence of a
significant main effect of treatment. Averaged across
subjects, in the placebo conditions the RDR was 1.18, the
upper limit was 480 pps, and the GDT was 2.93 ms. The
corresponding values after AUT00063 were 1.19, 447 pps,
and 2.93 ms. It is also worth noting that, despite the
reduction in the RDR andGDT between the two baseline
measures (sessions 1 and 3; BCorrelations Between
Sessions And Tasks^ in the BResults^ section), there was
no significant effect of period in the ANOVAs based on
the two post-treatment visits (Table 2).
It can be seen from Figs. 4 and 5 that two subjects,
S07 and S08, showed quite marked and opposite
differences between the AUT00063 and placebo tests,
and this would have contributed to the relatively large
confidence limits for the effect size of the upper limit.
Closer examination of the data suggest that the results
for subject S07, whose upper limits were 353 pps
and 978 pps in AUT00063 and placebo conditions,
respectively, were unreliable due to a poor correspon-
dence between the broken-stick function used to
estimate the upper limit and the raw data for the
placebo condition. That subject’s MPC pitch rank
functions are shown with the corresponding fits in Fig.
2a, b for the AUT00063 and placebo conditions
respectively. For the AUT00063 condition, which for
this subject corresponded to session 4, the fit is
reasonably good and the rms error between the
function and the raw data was 0.66, which was very
close to the average rms error across all subjects and
sessions of 0.65. In contrast, the fit for the placebo
condition was very poor, and the rms error of 1.19 was
the highest for any subject for that session. The rms
errors for subject S08 (fits not shown), whose upper
TABLE 2
Results of the ANOVAs performed to assess the potential effect of AUT00063 on the RDR, upper limit, and GDT. Data in the
second and third columns are adjusted for the effects of sequence and period
Geometric least-squares adjusted mean 95 % confidence (2-sided) Raw geometric mean p value (2-sided)
RDR
AUT00063 1.21 1.17–1.26 1.19
Placebo 1.20 1.17–1.23 1.18
AUT00063/placebo 1.01 0.96–1.06 1.01 0.63
Period effect 0.47
Sequence (carry over) effect 0.26
Upper limit
AUT00063 457 349–599 447
Placebo 491 402–600 480
AUT00063/placebo 0.93 0.67–1.30 0.93 0.65
Period effect 0.50
Sequence (carry over) effect 0.03
GDT
AUT00063 2.93 2.56–3.36 2.93
Placebo 2.96 2.68–3.28 2.93
AUT00063/Placebo 0.99 0.84–1.17 1.0 0.89
Period effect 0.20
Sequence (carry over) effect 0.98
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limits were 981 and 330 pps in the AUT00063 and
placebo conditions, were unexceptional, being 0.54
and 0.57 respectively. In order to investigate whether
the lack of a significant treatment effect for the upper-
limit measure could be attributed to poor fits, an
additional 1-way ANOVA (AUT00063 vs placebo) was
performed, in which the cases were weighted by the
inverse of the RMS errors. This also showed no
significant effect of treatment (F(1,20) = 0.019, p =
0.89)). Finally, we investigated whether any subject
showed a difference between the AUT00063 and
placebo conditions at the individual level. To do this,
we exploited the fact that, in each of the placebo
and AUT00063 sessions, 10 sub-blocks of the MPC
were obtained. We first selected, at random, five sub-
blocks from each condition and estimated the upper
limit from these ten sub-blocks combined. This was
then repeated and the difference between the upper
limit estimated from the first minus the second
sampling was calculated. This whole procedure was then
repeated 200 times to obtain the null distribution of
differences under the hypothesis of no difference
between the sessions; the 95 % confidence limits of this
distribution are shown by the shaded area in Fig. 6. We
then calculated the observed difference by calculating
the between-session difference obtained from five sub-
blocks in each condition, again with this procedure
repeated 200 times and with the estimated differences
averaged. This Btrue^ difference is shown by the solid
black line in Fig. 6. It can be seen that the difference for
no subject fell outside the 95 % confidence intervals of
the null distribution. These differences can be compared
to those obtained using our initial analysis based on all
ten blocks for each condition (solid red line). It can be
seen that, for most subjects, the results of the two analyses
are very close. The exceptions are the relatively large
differences observed for subjects 6 and 7 in our main
analysis (cf. Figs. 4 and 5), which were reduced when
estimated using the resampling method.
DISCUSSION
Comparisons with Other Studies: Overall
Performance and Across-Subject Correlations
The overall size of the RDRs, upper limits, and GDTs
reported here are broadly similar to those reported by
ourselves and others in studies that did not involve
any pharmacological intervention. The mean GDT of
2.9 ms reported here was slightly lower than the
average value of 5.1 ms obtained from Advanced
Bionics users by Bierer et al. (2015), who used very
similar methods to those used here, and falls within
the range of GDTs obtained by Garadat and Pfingst
(2011) for pulse trains presented at a level corre-
sponding to 90 % of the dynamic range. In a recent
study using almost identical methods to those used
here, Carlyon et al. (submitted) reported, for nine
Cochlear subjects tested 2 months after implant
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activation, a mean RDR of 1.23 and a mean upper
limit of 485 pps. These values are very close to the
RDR of 1.18 and upper limit of 480 pps reported here
for the placebo condition. The RDRs reported here
are also similar to the mean values of 1.22 reported by
Cosentino et al. (2016), of 1.16 or 1.28 (depending on
electrode) by Stahl & Macherey (2016), and of 1.25 by
Bahmer and Baumann (2013).
Some earlier studies have shown smaller RDRs. For
example, Moore and Carlyon (2005) analysed the
results of 19 listeners from five studies and reported
an average RDR of 1.073 at a 100-pps standard rate,
although with a large variation across subjects and
studies. Goldsworthy and Shannon (2014) showed
that extensive training on a rate discrimination task
produced significant reductions in RDRs, which, after
6-7 2-hour sessions, were approximately 1.04 at a rate
of 110 pps. Learning effects were also observed for the
RDRs measured in the present study, as evidenced by
the significant difference between sessions 1 and 3
and described in section BCorrelations Between
Sessions And Tasks^ in the BResults^ section. The
lower RDRs reported in some studies and the
presence of learning effects raises the possibility that
the larger RDRs reported here and elsewhere do not
reveal the Btrue^ limits of temporal sensitivity, and
that more central limitations in performance ob-
scured any potential benefit of AUT00063 in the
present study. We do not think this is likely because
studies that obtained similar RDRs to those observed
here have been shown to be sensitive to other
manipulations, such as effects of the electrode stimu-
lated (Cosentino et al. 2016; Stahl et al. 2016) and of
stimulus level (Carlyon et al. submitted). In addition,
we note that the between-session change in RDR
observed here was consistent with initial, perhaps
procedural, learning during the first session followed
by roughly constant performance thereafter: mean
RDRs in sessions 1–4 were 1.26, 1.19, 1.15, and 1.16.
As noted in BCorrelations Between Sessions And
Tasks^ in the BResults^ section, although perfor-
mance on each task correlated highly between
sessions 1 and 3, between-task correlations were not
significant, being − 0.20 between the RDR and upper
limit, − 0.27 between GDT and upper limit, and − 0.07
between the RDR and GDT. Those correlations are
smaller than reported by Cosentino et al. (2016),
which, for the same comparisons, were − 0.47 (t(8) =
1.50, p = 0.17), − 0.90 (t(8) = 5.84, p G 0.0001), and 0.43
(t(8) = 1.35, p = 0.21). Cosentino et al. suggested that
the significant correlation between the upper limit
and GDT might reflect a common neural limitation,
associated with sustained and temporally accurate
neural responses at high rates, between the two tasks.
They argued against a trivial explanation for the
correlation, which is that it reflected some non-
specific and possibly cognitive between-subject differ-
ences, because the correlation between upper limit
FIG. 6. Results of the resampling analysis of the upper-limit data.
The ordinate shows the difference between the logarithms of the
upper limits in the AUT00063 and placebo conditions (positive
values reflect an increase). The solid black line shows the mean of
the values obtained for each subject from the broken-stick fits to 200
resamplings of 5 sub-blocks. The shaded area shows the 95 %
confidence intervals of the null distribution (see text for details). The
solid red line shows the values obtained from our original analysis
(Figs. 4 and 5), based on the broken-stick fits to the data from all 10
sub-blocks
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and GDT was significantly stronger than that between
the upper limit and the RDR. The much weaker
correlation between upper limit and GDT observed
here could be due to the factors limiting performance
differing between the two subject groups, or may
reflect differences in methods between the two
studies. Cosentino et al. (2016) used a different
method of estimating the upper limit, and each
subject’s scores were obtained from the average of
repeated measures on each of four different elec-
trodes. When we combined the p values from the two
studies using Stouffer’s test, it remained significant at
p = 0.009.
Efficacy
The 95 % confidence limits shown in Table 2 impose
substantial constraints on the largest possible size of
any beneficial effect of AUT00063 for this population
and for the dosage size and method used here. The
largest improvement due to AUT00063 that fell within
the 95 % confidence limits would have been a
reduction in the RDR of about 4 %, an increase in
the upper limit of about 30 %, and an approximate
16 % reduction in the GDT. The corresponding
maximum dele ter ious e f fec t s would have
corresponded to 6 %, 33 %, and 17 % respectively.
One possible explanation for the absence of an
effect of AUT00063 is that, although our subjects had
all undergone extensive periods of auditory depriva-
tion, this was followed by months or years of hearing
through their CI, which then restored temporal
processing even in the absence of the drug. Vollmer
et al. (2005) reported that the upper limit of phase
locking in the IC was higher in a group of juvenile
deafened cats that had been implanted and
stimulated chronically for 21 weeks, compared to an
unstimulated group, and was similar to that of a
control group that had grown up with normal
hearing. However, it appears that in humans, the
restorative effects of chronic stimulation are not
complete. Carlyon et al. (submitted) measured the
psychophysical upper limit and RDR in nine CI users
on the day of activation and 2, 6, and 9 months later.
The RDR dropped and the upper limit increased
significantly between the day of activation (Bswitch-
on^) and 2 months later, but these changes were
modest, corresponding to a 36 % increase in the
upper limit (95 % confidence interval 20–35 %) and a
reduction in the RDR by a factor of 1.06 (95 %
confidence interval 1.005–1.210). They noted that
these changes may have been partly due to the
increases in stimulation level needed at 2 months to
maintain the same loudness as at switch-on. Impor-
tantly, substantial across-subject differences remained,
and the upper limit for most subjects was substantially
lower than the 700 pps obtained with NH listeners
presented with bandpass filtered pulse trains
(Macherey and Carlyon 2014). These across-listener
differences have also been shown in one study to
correlate with the duration of deafness in a group of
subjects who had been using their CIs for months or
years (Cosentino et al. 2016).
The demonstrated sensitivity of the RDR and upper
limit tests to modest effects of chronic stimulation and
level (Carlyon et al. submitted), combined with the
good test-retest reliability observed here for all
measures, makes it unlikely that the absence of a
significant treatment effect can be attributed to low
power or to the use of unreliable methods. As noted
above, Carlyon et al. (submitted) reported statistically
significant changes in the upper limit and RDR from
the day of activation to 2 months later, and, regardless
of whether those improvements were affected by
changes in stimulation level, the study demonstrates
the sensitivity of the methods used here. Furthermore,
the tests used here were designed to identify improve-
ments in the processing of TFS, via sustained tempo-
rally accurate neural firing, which was expected to be
the main effect of AUT00063.
Our results contrast with the positive effects
observed with acoustic stimulation in animal models
and described in the BIntroduction^, and particularly
with the finding that AUT00063 can improve fine
temporal processing in Oubain-treated mice
(Chambers et al. 2017). There are several possible
reasons for this discrepancy. Considering the dosages
used, plasma concentration of AUT00063 was not
assessed in the present study; however, the same
(800 mg) doses of AUT00063 were administered to
subjects with tinnitus in a separate trial (Autifony
Therapeutics 2014) and resulted in drug concentra-
tions consistent with those found to be effective in
animal models; AUT00063, with mean (median)
plasma levels of AUT00063 of 4818.82 (4704.50)
ng/ml. However, since this mechanism of drug action
has not been explored in humans until now, it is not
possible to determine whether humans are more or
less sensitive to drugs modulating Kv3 channels in the
auditory brain. A notable difference in study design
between the present study and the preclinical mea-
sures obtained with animal models is the chronic drug
administration and testing used here compared to the
acute treatment evaluated in successful animal inter-
ventions (Rybalko et al. 2014; Chambers et al. 2017;
Anderson et al. 2018; Glait et al. 2018). Indeed, there
would be considerable value in a future study
examining the effects of acute administration of
AUT00063 on human hearing. If such an effect were
obtained, a useful next step would be to investigate
any possible adaptation to the drug. What we can
conclude is that any beneficial effect of AUT00063 on
CARLYON ET AL.: Evaluation of Possible Effects of a Potassium Channel Modulator
temporal processing by human CI listeners, at the
dosage used here, is at most small and that we have no
evidence that such an effect exists.
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